Longitudinal profiling of serum ADAM17 across clinical stages in multiple myeloma: a dynamic biomarker and its association with T cell alterations
Our data identify ADAM17 as an easily quantifiable, longitudinal biomarker that concurrently reflects tumor development stage and renal function damage in MM patients. Incorporation of ADAM17 into existing risk algorithms may enhance prognostic precision and enable earlier, patient-tailored intervention.
Authors
- Shumei Xiao (ORCID: https://orcid.org/0000-0001-5326-2846)
- Jiao Qu
- Qiubai LI
- Yulin Cao
- Xingshuo Bao
- Zhichao Chen
- Di Wu
- Yancheng Li
- Chenchen Li
- Lei Chen
Institutions
- First People’s Hospital of Jingmen (CN)
- Wuhan Union Hospital (CN)
- Jingzhou Central Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Molecular Biosciences
- Published
- 2026-01-30
- DOI
- https://doi.org/10.3389/fmolb.2026.1768193
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Hubei Province